BLTE
HealthcareBelite Bio, Inc
$159.42
+$0.15 (+0.09%)
Jan 5, 2026
Price History (1Y)
Analysis
Belite Bio, Inc is a biotechnology company operating in the healthcare sector. With a market capitalization of $5.98B, it falls into the larger-scale category among its peers. The company's industry classification aligns with the broader biotechnology segment, and with 25 employees on board, Belite Bio has a relatively small workforce. Belite Bio exhibits poor profitability indicators, as evidenced by its gross margin, operating margin, and profit margin all being at 0%. This is reflected in its net income of $-62,387,000 (TTM) and EBITDA of $-67,405,000. Its return on equity stands at -32.3%, while the return on assets sits at -21.2%. The company's balance sheet shows a substantial cash reserve of $275.61M against a relatively minor debt burden of $510,000. Belite Bio has a forward P/E ratio of -268.38 and an EV/EBITDA of -78.36, which may raise questions about its valuation in relation to its earnings performance. The absence of revenue growth (YoY) and earnings growth (YoY) data prevents further analysis of this aspect. Given the lack of dividend information, a dividend yield is not applicable.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Visit website →Key Statistics
- Market Cap
- $5.98B
- P/E Ratio
- N/A
- 52-Week High
- $169.75
- 52-Week Low
- $49.00
- Avg Volume
- 179.94K
- Beta
- -1.46
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 25